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OPINION
Pharmacotherapy treatment of depression 
in patients with neurodegenerative diseases: 
where are we?
Tratamento farmacológico da depressão em pacientes com doenças neurodegenerativas: 
onde nós estamos?
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Dear Editors,
According to a Brazilian study in a population of over 
65-years-old, the prevalence rate of Alzheimer’s disease 
(AD) is 3.9%1. It is well-known that depression is a com-
mon and disabling disorder in this population, but the ad-
vantage of antidepressant use for its treatment remains 
uncertain.
A recent study has evaluated the efficacy of sertraline and 
mirtazapine in the treatment of depression in patients with 
AD2. The authors evaluated 218 patients with depression di-
vided into three groups (sertraline, mirtazapine, and place-
bo). No differences were found among the groups for the out-
come response and remission of depression. This study was 
conducted with appropriate time (outcomes measured on 13 
and 39 weeks) and doses. Adverse side effects were signifi-
cantly greater in the group using antidepressants when com-
pared to the placebo group. The authors concluded that it is 
needed to reconsider the use of antidepressants as first line 
treatment of depression in AD.
Another neurodegenerative disease, Parkinson’s disease 
(PD), affects approximately 3.3% of patients over 64 years3. 
Similarly, depression is highly prevalent in this population 
and may affect 25.5% of PD patients, according to a study 
conducted with a sample of a Brazilian tertiary hospital4. 
In general, antidepressants are used to treat depression in 
PD, however, a recent meta-analysis concluded that there 
is no sufficient evidence to indicate differences in rates of 
response or remission in depression in PD patients using 
selective ser otonin reuptake inhibitor antidepressants or 
placebo5. The review also highlights that there are few clin-
ical trials conducted so far and that in these studies the 
small samples sizes make definitive conclusions more dif-
ficult to reach.
It is also important to address that patients with depres-
sion and neurodegenerative diseases may not similarly re-
spond to the antidepressants commonly used in patients 
without these neurological comorbidities.
The diagnosis of depression in AD and PD can be chal-
lenging, since some symptoms of these neurodegenerative 
diseases overlap depression symptoms. For instance, sleep 
and appetite disturbance, apathy and psychomotor retarda-
tion are prevalent in both conditions. Thus DSM-IV criteria 
could not be valid in these cases. Furthermore, pathophys-
iological mechanisms related to the emergence of depres-
sion in these diseases could be different or even part of the 
neurodegenerative process.
As noted above, many questions can be made from these 
findings and all of them evidence to the need of more re-
search and a careful examination of the use of the antidepres-
sant for the treatment of neurodegenerative diseases in clini-
cal practice.
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